Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

SIMPLE SUMMARY: Immunotherapy has improved the outcome of relapsed/refractory B-lymphoblastic leukemia. However, little is known about the outcome after recurrence and re-treatment with monoclonal antibodies. The aim of our retrospective study was to evaluate the efficacy and safety of blinatumomab...

Descripción completa

Detalles Bibliográficos
Autores principales: Fracchiolla, Nicola Stefano, Sciumè, Mariarita, Papayannidis, Cristina, Vitale, Antonella, Chiaretti, Sabina, Annunziata, Mario, Giglio, Fabio, Salutari, Prassede, Forghieri, Fabio, Lazzarotto, Davide, Lunghi, Monia, Imovilli, Annalisa, Scappini, Barbara, Bonifacio, Massimiliano, Dargenio, Michelina, Gurrieri, Carmela, Todisco, Elisabetta, Defina, Marzia, Del Principe, Maria Ilaria, Zappasodi, Patrizia, Cerrano, Marco, Santoro, Lidia, Tagliaferri, Elena, Barozzi, Enrico, De Roberto, Pasquale, Canzi, Marta, Buzzatti, Elisa, Sartor, Chiara, Passamonti, Francesco, Foà, Robin, Curti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526797/
https://www.ncbi.nlm.nih.gov/pubmed/37760592
http://dx.doi.org/10.3390/cancers15184623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526797/
https://www.ncbi.nlm.nih.gov/pubmed/37760592
http://dx.doi.org/10.3390/cancers15184623

Ejemplares similares